This directory serves as a resource listing of active biotech that develop therapeutics, diagnostics and/or medtech. The companies listed in this directory are not representative of the companies that are active members of the Biotech and Money community.
Add / Amend your company listing for free
(only active biotech ie. therapeutic, diagnostic and medtech companies are eligible for listing)
Ireland
BCO Pharma focuses on pediatric care. The company?s lead product (being developed by BrePco) is a unique formulation of a first line inotrope and is expected to enter phase III trials this year.
Dignity Sciences Ltd discovers and develops scientifically innovative healthcare solutions that improve the quality of life for people with diseases for which current therapies are unsatisfactory. The company have broad portfolio of preclinical and clinical stage candidates that are being progressed for the treatment of skin, cardiovascular and pulmonary diseases.
Genable Technologies Ltd. is a privately held, venture backed, Dublin (Ireland) based bio-pharmaceutical company developing new gene medicines to treat "dominant" genetic diseases.
Genable utilizes well-established, clinically safe & effective AAV vectors to obtain expression of RNA interference (RNAi) molecules which suppress the expression of both the faulty and normal gene copies and replaces this with a gene subtly altered to become refractory to suppression but still encoding a normal wild type protein.
The combination of suppression and replacement (S&R) overcomes the significant hurdle in dominant disease of mutation variability by eliminating the need to target specific mutations in a wide range of disorders. Genable's technology is protected by a broad suite of granted patents and patent applications in the USA, EU and worldwide.
Genable utilizes well-established, clinically safe & effective AAV vectors to obtain expression of RNA interference (RNAi) molecules which suppress the expression of both the faulty and normal gene copies and replaces this with a gene subtly altered to become refractory to suppression but still encoding a normal wild type protein.
The combination of suppression and replacement (S&R) overcomes the significant hurdle in dominant disease of mutation variability by eliminating the need to target specific mutations in a wide range of disorders. Genable's technology is protected by a broad suite of granted patents and patent applications in the USA, EU and worldwide.
IBL is an early stage drug development company which have a portfolio of innovative preclinical oncology small molecule therapeutics. The company's aim is to raise funds to bring these assets through preclinical development to early clinical trials.
Newport Pharmaceuticals Ltd. engaged in the discovery of products for the treatment of infectious diseases, immunological disorders, and related conditions. The company offers Inosine Acedoben Dimepranol, a synthetic purine derivative.
Opsona Therapeutics is a leading immunology drug development company, focused on novel therapeutic approaches to key targets of the innate immune system associated with a wide range of major human diseases, including autoimmune and inflammatory diseases, with specific focus on Solid Organ transplantation and Oncology.
Opsona's lead product, a fully humanized monoclonal IgG4 antibody (OPN-305) targeting Toll-like-receptor-2 (TLR2) has demonstrated activity in a number of preclinical models and has been tested in a Phase I clinical trial in healthy volunteers. Recently the company has initiated a three-part multi-centred, double blinded and placebo controlled Phase II clinical study to evaluate the safety, tolerability and efficacy of OPN-305 in renal transplant patients at high risk of Delayed Graft Function (DGF) as the first clinical indication for the development of OPN-305. The first part of this Phase II has been completed in transplant patients. The second part is ongoing in transplant patients.
OPN-305 has obtained EMA and FDA orphan drug status in Solid Organ Transplantation. Opsona has been awarded a EUR 5.9 million grant from the European Commission in 2010 to lead a European framework 7 (FP7) consortium of research and clinical groups (MABSOT )to help advance OPN-305 through clinical development.
Opsona?s second programme is targeting the Inflammasome, strategically complementing our pipeline of innate immune modulators. Pathologies such as gouty arthritis, Muckle-Wells syndrome or CINCA/NOMID have been shown to be dependent on Inflammasome activity. Early development studies have confirmed drugability of the Inflammasome. Opsona is actively seeking a partnering opportunity for its small molecule Inflammasome inhibitor programme.
Opsona's lead product, a fully humanized monoclonal IgG4 antibody (OPN-305) targeting Toll-like-receptor-2 (TLR2) has demonstrated activity in a number of preclinical models and has been tested in a Phase I clinical trial in healthy volunteers. Recently the company has initiated a three-part multi-centred, double blinded and placebo controlled Phase II clinical study to evaluate the safety, tolerability and efficacy of OPN-305 in renal transplant patients at high risk of Delayed Graft Function (DGF) as the first clinical indication for the development of OPN-305. The first part of this Phase II has been completed in transplant patients. The second part is ongoing in transplant patients.
OPN-305 has obtained EMA and FDA orphan drug status in Solid Organ Transplantation. Opsona has been awarded a EUR 5.9 million grant from the European Commission in 2010 to lead a European framework 7 (FP7) consortium of research and clinical groups (MABSOT )to help advance OPN-305 through clinical development.
Opsona?s second programme is targeting the Inflammasome, strategically complementing our pipeline of innate immune modulators. Pathologies such as gouty arthritis, Muckle-Wells syndrome or CINCA/NOMID have been shown to be dependent on Inflammasome activity. Early development studies have confirmed drugability of the Inflammasome. Opsona is actively seeking a partnering opportunity for its small molecule Inflammasome inhibitor programme.
Sigmoid Pharma Limited is a specialty pharma company who identify and create meaningful new therapies for unmet clinical needs in gastrointestinal and immunological diseases and disorders. The company is advancing a pipeline of products for the treatment of gastrointestinal diseases and disorders, with priority focus on the lead product, CyCol
TriMod Therapeutics Ltd is an early stage biotechnology company whose primary R&D focus is dedicated to developing novel platform technologies to treat cancer and autoimmune diseases. Company's TriMoVac technology enhances the patients' immune response to the tumour and promotes its eradication by attenuating its' immune subversion strategies using a combination of (1) a TLR agonist; (2) a kinase inhibitor; and (3) a tumour antigen of choice.
Trino is a drug discovery and early drug development company focused on Immunomodulatory therapeutics. The company is developing drug candidates from a novel, proprietary, class of drugs based on indane dimers derived from a Taiwanese fern. Its lead candidate is a potential first-in-class drug for the treatment of inflammatory bowel disease (IBD), which could be used in both ulcerative colitis (UC) and Crohn?s disease (CD).
Westgate Biological Ltd. develops, markets, and licenses a technology of natural antimicrobial agents that are effective against gram positive and gram negative bacteria, fungi, yeast, and moulds for use in pharmaceutical and personal care products. The company also develops formulations based on its antimicrobial agents for use in hospital/healthcare acquired infections.